Key Highlights
• Verici Dx LSE:VRCI fell 11.11% on 21 September 2026, according to the market snapshot.
• The decline occurred on the same day that Verici Dx announced the planned Q4 2026 launch of TranscripTx, a new genetic test designed specifically for the transplant community.
• TranscripTx uses next-generation sequencing to identify genetic variants in peripheral blood RNA that may help assess treatment response and longer-term graft-failure risk.
• The company is expanding beyond its established Tutivia kidney-transplant rejection test and building a broader transplant diagnostics platform.
• FY25 Revenue reached US$3.7 million, including US$2.9 million from Tutivia testing, while 1,173 Tutivia tests were ordered during the year.
• Q1 2026 Tutivia testing volumes increased to 392 tests, up 32% from Q4 2025, with seven new transplant centres beginning to order the test.
• The company raised approximately £2.6 million gross in June 2026, while management previously indicated that the funding, together with commercial progress, supported its expected cash runway towards the end of 2026.
Why Is Verici Dx LSE:VRCI in Focus Today?
Verici Dx has become a closely watched healthcare stock on 21 September 2026 after announcing the planned commercial launch of TranscripTx in Q4 2026.
The new test is designed for transplant patients and uses next-generation sequencing to measure genetic variants found in peripheral blood RNA. These genetic variations may provide information about how transplant recipients respond to therapies and their longer-term risk of graft failure.
The announcement is strategically important because it broadens Verici Dx's commercial product portfolio beyond Tutivia.
The company is positioning TranscripTx as a transplant-focused genetic test that can also support Drug Development and clinical trials. It incorporates AI-enabled evidence-based gene selection and is designed to detect clinically relevant splice variants that cell-free DNA technologies cannot detect.
Why Did Verici Dx LSE:VRCI Fall 11.11% on 21 September 2026?
The 11.11% fall shown for LSE:VRCI on 21 September 2026 occurred despite the company announcing the TranscripTx launch.
Importantly, the latest company announcement itself was focused on a new product launch and did not identify a negative operational development responsible for the day's decline.
Therefore, the 11.11% move should not automatically be attributed to TranscripTx.
The shares remain highly sensitive to commercial adoption, cash requirements, revenue visibility and investor expectations because Verici Dx is still transitioning from a development-stage diagnostics Business into a more commercially established company.
The market is likely assessing whether new products can translate the company's technology and clinical data into Recurring Revenue at sufficient scale.
What Is TranscripTx and Why Does It Matter for LSE:VRCI?
TranscripTx is a new genetic diagnostic specifically designed for transplant patients.
The test will be offered as a laboratory-developed test through Verici Dx's CLIA-certified and CAP-accredited laboratory in the United States. It uses next-generation sequencing to analyse genetic variants in peripheral blood RNA.
The test is intended to provide information that could help clinicians understand differences in patient response to therapy and longer-term graft-failure risk.
Verici Dx also sees potential applications in drug development and clinical trials.
This is significant because the company is attempting to use its existing clinical data, biological samples and RNA-diagnostics expertise to develop additional commercial products without relying exclusively on Tutivia.
How Important Is Tutivia to Verici Dx?
Tutivia remains the company's principal commercial product.
Tutivia is a post-kidney-transplant test designed to help detect acute rejection. Verici Dx reported that 1,173 Tutivia tests were ordered during FY25, compared with 334 during FY24. Revenue recognised from Tutivia reached approximately US$2.9 million during FY25.
The company subsequently reported continued acceleration during Q1 2026.
Tutivia testing volumes reached 392 tests in Q1 2026, representing a 32% increase compared with the 296 tests ordered during Q4 2025. Seven additional transplant centres also began ordering the test during the quarter.
This testing-volume trajectory is one of the most important indicators for investors because increasing utilisation should provide greater visibility over future testing revenue.
Why Is Medicare Coverage Important for LSE:VRCI?
Verici Dx has secured Medicare coverage for Tutivia, which management said provides coverage across an estimated 68% of US transplant tests.
The company has also secured a contract with Blue Cross Blue Shield of Illinois, providing contracted pricing and in-network status for covered patients.
These developments are important because reimbursement is a key consideration for adoption of diagnostic tests.
Greater payer coverage can potentially reduce barriers for healthcare providers and patients, although actual revenue depends on test volumes, reimbursement rates, commercial payer arrangements and the company's ability to expand adoption.
What Are Verici Dx's Latest Financial Numbers?
Verici Dx reported FY25 revenue of US$3.7 million, compared with US$3.3 million in FY24.
Tutivia generated US$2.9 million of recognised revenue, while licensing income contributed approximately US$0.8 million. Adjusted EBITDA remained negative at approximately US$6.2 million.
Cash at 31 December 2025 was approximately US$3.3 million, while Accounts Receivable stood at approximately US$1.5 million.
Following the period end, Verici Dx raised approximately £2.6 million gross in June 2026.
This means Cash Management and the pace at which commercial revenues expand remain important considerations for LSE:VRCI.
What Other Products Could Support Verici Dx Growth?
Verici Dx is developing a broader pipeline around transplant diagnostics.
In addition to Tutivia and TranscripTx, the company is advancing PTRA and Protega.
PTRA has been moving towards commercialisation, while Protega has been progressing towards research-use-only sales. The company has also identified opportunities involving discovery and clinical-trial support, data Assets and potential urine-based testing.
This gives LSE:VRCI exposure to several potential revenue streams rather than relying entirely on one diagnostic product.
What Are Investors Watching Next for Verici Dx LSE:VRCI?
The key areas include:
• Q4 2026 launch of TranscripTx
• Initial customer adoption of TranscripTx
• Tutivia testing volumes
• New transplant-centre additions
• Medicare and commercial reimbursement
• Revenue growth
• Cash consumption
• PTRA commercial sales
• Protega development
• New strategic partnerships
• Clinical and real-world evidence supporting the diagnostic portfolio
The successful launch and adoption of TranscripTx could provide an important test of Verici Dx's ability to commercialise additional products from its existing technology and data platform.
What Could Drive the Next Move in LSE:VRCI?
The next important catalyst could be evidence of commercial traction for TranscripTx following its planned Q4 launch.
Continued growth in Tutivia testing volumes is another important factor. The Q1 2026 increase to 392 tests provides evidence of rising utilisation, but investors will want to see whether this momentum continues across subsequent quarters.
Financial performance will also remain important.
Verici Dx needs to increase recurring diagnostic revenue while managing its operating expenditure and cash requirements. The pace of revenue growth relative to cash consumption will therefore remain a key metric.
What Is the Outlook for Verici Dx LSE:VRCI?
The 11.11% decline on 21 September 2026 highlights the continued Volatility surrounding LSE:VRCI, even as the company expands its commercial diagnostics portfolio.
The latest TranscripTx announcement provides a new potential growth avenue, while Tutivia remains the principal revenue-generating diagnostic. The company is also developing PTRA, Protega and additional applications around its clinical data and biological-sample repository.
The next major milestones are likely to be the Q4 TranscripTx launch, Tutivia testing volumes, reimbursement developments, revenue growth and cash management.






Please wait processing your request...